Immuron Limited (AU:IMC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Immuron Limited reports robust sales growth for its gastrointestinal supplement Travelan, with a 13% increase globally in the September 2024 quarter, led by a significant 48% rise in North America and steady growth in Australia. The company continues to expand its market presence, securing additional pharmacy group partnerships in Australia and increasing distribution channels across North America and Canada.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
